Scholarlink

<p>Colorectal cancer (CRC) continues to be the largest reason for disease-related illnesses and fatalities globally, emphasizing the critical necessity finding new along with affordable therapy approaches. Biguanides, particularly metformin and phenformin, have emerged as promising anticancer agents by perturbing metabolic networks that are critical for cancer cell survival. Extensive preclinical and clinical investigations indicate that biguanides exert their anticancer effects in colorectal cancer chiefly by altering mitochondrial bioenergetics and downstream signalling pathways. The primary approach includes inhibiting cellular respiration cycle complexes I, thereby lowering phosphate oxidation along with the production of ATP while increasing the AMP/ATP balance. This physiological strain stimulates AMP-activated protein kinase (AMPK), a crucial physiological detector, which suppresses mammalian target of rapamycin complex 1 (mTORC1) signalling by inhibiting protein production, growth of cells and tumour development. Biguanides affect insulin/IGF-1 signalling, oxidative balance, and cellular inflammation through HIF-1α and NF-κB, in addition to AMPK-related processes. Significantly, specific involvement throughout biguanides seems to be highly contextually regulated by tumour genetics, energy metabolism characteristics, gastrointestinal microbiota, as well as nutritional accessibility, which somewhat could clarify the variance in patient outcomes among CRC subsets. Recent investigations reveal that biguanides improve therapeutic sensitivity to conventional chemo-radiotherapy and promote ferroptosis and additional non-apoptotic death pathways, highlighting their translational potential. This review integrates molecular and signalling insights to elucidate how biguanides engage key metabolic targets in CRC, leading to coordinated metabolic reprogramming and tumour suppression. A better knowledge of specific involvement as well as prospective indicators could assist with identifying individuals along with maximize the reconfiguration of biguanides as supplementary or independent medicines in colon cancer treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Target engagement of biguanides in colorectal carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Poulami Patra,
  • Rajat Subhra Dutta,
  • Supriya Sahu

摘要

Colorectal cancer (CRC) continues to be the largest reason for disease-related illnesses and fatalities globally, emphasizing the critical necessity finding new along with affordable therapy approaches. Biguanides, particularly metformin and phenformin, have emerged as promising anticancer agents by perturbing metabolic networks that are critical for cancer cell survival. Extensive preclinical and clinical investigations indicate that biguanides exert their anticancer effects in colorectal cancer chiefly by altering mitochondrial bioenergetics and downstream signalling pathways. The primary approach includes inhibiting cellular respiration cycle complexes I, thereby lowering phosphate oxidation along with the production of ATP while increasing the AMP/ATP balance. This physiological strain stimulates AMP-activated protein kinase (AMPK), a crucial physiological detector, which suppresses mammalian target of rapamycin complex 1 (mTORC1) signalling by inhibiting protein production, growth of cells and tumour development. Biguanides affect insulin/IGF-1 signalling, oxidative balance, and cellular inflammation through HIF-1α and NF-κB, in addition to AMPK-related processes. Significantly, specific involvement throughout biguanides seems to be highly contextually regulated by tumour genetics, energy metabolism characteristics, gastrointestinal microbiota, as well as nutritional accessibility, which somewhat could clarify the variance in patient outcomes among CRC subsets. Recent investigations reveal that biguanides improve therapeutic sensitivity to conventional chemo-radiotherapy and promote ferroptosis and additional non-apoptotic death pathways, highlighting their translational potential. This review integrates molecular and signalling insights to elucidate how biguanides engage key metabolic targets in CRC, leading to coordinated metabolic reprogramming and tumour suppression. A better knowledge of specific involvement as well as prospective indicators could assist with identifying individuals along with maximize the reconfiguration of biguanides as supplementary or independent medicines in colon cancer treatment.

Graphical Abstract